Pulmonx Corp LUNG.OQ LUNG.O is expected to show a fall in quarterly revenue when it reports results on March 4 for the period ending December 31 2025
The Redwood City California-based company is expected to report a 8.6% decrease in revenue to $21.728 million from $23.77 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Pulmonx Corp is for a loss of 39 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pulmonx Corp is $4.50, about 184.8% above its last closing price of $1.58
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.42 | -0.42 | -0.34 | Beat | 18.7 |
Jun. 30 2025 | -0.40 | -0.37 | -0.38 | Missed | -1.8 |
Mar. 31 2025 | -0.39 | -0.37 | -0.36 | Beat | 3.4 |
Dec. 31 2024 | -0.44 | -0.45 | -0.33 | Beat | 26.3 |
Sep. 30 2024 | -0.45 | -0.45 | -0.36 | Beat | 19.7 |
Jun. 30 2024 | -0.42 | -0.43 | -0.35 | Beat | 17.7 |
Mar. 31 2024 | -0.45 | -0.46 | -0.36 | Beat | 22 |
Dec. 31 2023 | -0.38 | -0.41 | -0.36 | Beat | 11.6 |
This summary was machine generated March 2 at 21:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments